By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Sanofi SA on Tuesday said Libtayo showed clinically meaningful and durable responses in second-line advanced basal cell carcinoma in an open-label phase 2 study.

The companies said the study involves patients who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy, for whom there are currently no approved treatments.

Regeneron and Sanofi said they plan to make regulatory filings this year.

Basal cell carcinoma, a skin cancer, is the most common cancer worldwide.

Sanofi and Regeneron last week said they had stopped a pivotal phase 3 trial of Libtayo in advanced non-small cell lung cancer early due to a highly significant improvement in positive overall survival.

Regeneron, of Tarrytown, N.Y., and France's Sanofi are jointly developing and commercializing Libtayo under a global collaboration agreement.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 05, 2020 10:42 ET (14:42 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Sanofi (NASDAQ:SNY)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Sanofi
Grafico Azioni Sanofi (NASDAQ:SNY)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Sanofi